<p>Foresite Capital Management V LLC 在最近向證券交易委員會提交的 13F 表格中表示，在第二季度將其在 Lyell Immunopharma, Inc. (NASDAQ:LYEL - 免費報告) 的持股減少了 95.0%。該公司在此期間出售了 7,726,395 股後，持有 406,652 股該公司的股票。Lyell Immunopharma 佔 Foresite Capital Management V LLC 投資組合的約 4.5%，使其成為第六大持股。Foresite Capital Management V LLC 在最近一個季度末持有的 Lyell Immunopharma 的股份約佔 2.63%，價值 3,595,000 美元。</p>
<p>其他幾家大型投資者最近也調整了對該公司的持股。Almitas Capital LLC 在第一季度將其在 Lyell Immunopharma 的股份增加了 136.3%。Almitas Capital LLC 目前持有 2,482,606 股該公司的股票，價值 1,336,000 美元，此前在此期間又購買了 1,432,086 股。Nuveen LLC 在第一季度購買了 Lyell Immunopharma 的新股份，價值約 345,000 美元。Acadian Asset Management LLC 在第一季度將其在 Lyell Immunopharma 的持股增加了 204.2%。Acadian Asset Management LLC 目前持有 660,899 股該公司的股票，價值 354,000 美元，此前又購買了 443,614 股。最後，AQR Capital Management LLC 在第一季度將其在 Lyell Immunopharma 的股份增加了 773.5%。AQR Capital Management LLC 目前持有 174,279 股該公司的股票，價值 94,000 美元，此前在上個季度又購買了 154,327 股。目前，66.05% 的股票由機構投資者持有。</p>
<p>獲取 <strong>Lyell Immunopharma</strong> 的提醒：</p>
<h2>華爾街分析師觀點</h2>
<p>幾位股票研究分析師最近對該股票發佈了報告。Wall Street Zen 在 9 月 1 日的研究報告中將 Lyell Immunopharma 的股票評級從 “賣出” 上調至 “持有”。HC Wainwright 在週一重申了 “中性” 評級，並將 Lyell Immunopharma 的目標價設定為 20.00 美元（之前為 10.00 美元）。最後，Weiss Ratings 在 10 月 8 日的報告中重申了對 Lyell Immunopharma 的 “賣出（d-）” 評級。一位股票研究分析師對該股票給予了持有評級，另一位則給予了賣出評級。根據 MarketBeat.com 的數據，Lyell Immunopharma 目前的共識評級為 “減持”，共識目標價為 20.00 美元。</p>
<p><strong>查看我們關於 Lyell Immunopharma 的最新報告</strong></p>
<h2>Lyell Immunopharma 價格表現</h2>
<p>NASDAQ:LYEL 的股票在週二開盤價為 22.72 美元。該公司的 50 日移動平均價格為 16.54 美元，200 日移動平均價格為 12.41 美元。Lyell Immunopharma, Inc. 的一年最低價為 7.65 美元，一年最高價為 22.99 美元。該股票的市值為 4.8212 億美元，市盈率為 -0.99，貝塔值為 -0.07。</p>
<p>Lyell Immunopharma (NASDAQ:LYEL - 獲取免費報告) 最近在 11 月 12 日宣佈了其季度財報。該公司報告本季度每股收益為（2.13 美元），超出市場共識預期的（2.81 美元）0.68 美元。Lyell Immunopharma 的股本回報率為 -96.68%，淨利潤率為 -794,292.69%。該公司在本季度的收入為 0.02 萬美元，而分析師的預期為 0.01 萬美元。分析師預計，Lyell Immunopharma, Inc. 在當前財政年度的每股收益將為 -0.78。</p>
<h2>Lyell Immunopharma 公司簡介</h2>
<p>（免費報告）</p>
<p>Lyell Immunopharma, Inc. 是一家臨牀階段的細胞治療公司，開發針對實體腫瘤患者的 T 細胞重編程技術。該公司利用體外基因重編程技術（如 c Jun 過表達和 NR4A3 基因敲除）開發療法，以賦予 T 細胞抵抗疲勞的能力；以及體外表觀遺傳重編程技術，包括 Epi R 以生成具有持久乾性的人羣 T 細胞，以及 Stim R，一種專有合成細胞仿生物。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Lyell Immunopharma</li>
<li>如何計算投資回報率 (ROI)</li>
<li>D-Wave：是時候買入了嗎？還是下跌才剛剛開始？</li>
<li>金融服務股票投資</li>
<li>Hims、Block 和 NRG 剛剛啓動了大規模股票回購</li>
<li>英國市場假期有哪些？如何投資和交易</li>
<li>零售收益匯總：沃爾瑪表現優異，塔吉特在第三季度下滑</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Lyell Immunopharma 嗎？</h2>
<p>在考慮 Lyell Immunopharma 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Lyell Immunopharma 並不在名單上。</p>
<p>雖然 Lyell Immunopharma 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

LYEL

<p>Foresite Capital Management V LLC 在第二季度根據其最新的 SEC 文件減少了對 Lyell Immunopharma, Inc.的持股，降幅達到 95%。該公司目前持有 406,652 股，較之前的 810 萬股大幅減少，使 Lyell 成為其第六大持股。機構投資者持有 Lyell 股票的 66.05%。分析師對該股票的評級意見不一，普遍評級為 “減持”，目標價格為 20.00 美元。Lyell 的股票開盤價為 22.72 美元，市值為 4.8212 億美元</p>

<p>Foresite Capital Management V LLC trimmed its holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 95.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 406,652 shares of the company's stock after selling 7,726,395 shares during the period. Lyell Immunopharma comprises about 4.5% of Foresite Capital Management V LLC's investment portfolio, making the stock its 6th largest holding. Foresite Capital Management V LLC owned about 2.63% of Lyell Immunopharma worth $3,595,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Foresite Capital Management V LLC 在最近向證券交易委員會提交的 13F 表格中表示，在第二季度將其在 Lyell Immunopharma, Inc. (NASDAQ:LYEL - 免費報告) 的持股減少了 95.0%。該公司在此期間出售了 7,726,395 股後，持有 406,652 股該公司的股票。Lyell Immunopharma 佔 Foresite Capital Management V LLC 投資組合的約 4.5%，使其成為第六大持股。Foresite Capital Management V LLC 在最近一個季度末持有的 Lyell Immunopharma 的股份約佔 2.63%，價值 3,595,000 美元。</p>
</div><p>Several other large investors also recently modified their holdings of the business. Almitas Capital LLC raised its position in shares of Lyell Immunopharma by 136.3% during the first quarter. Almitas Capital LLC now owns 2,482,606 shares of the company's stock worth $1,336,000 after purchasing an additional 1,432,086 shares during the period. Nuveen LLC bought a new stake in Lyell Immunopharma during the 1st quarter worth approximately $345,000. Acadian Asset Management LLC raised its holdings in Lyell Immunopharma by 204.2% during the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company's stock worth $354,000 after buying an additional 443,614 shares during the period. Finally, AQR Capital Management LLC lifted its stake in Lyell Immunopharma by 773.5% in the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company's stock valued at $94,000 after buying an additional 154,327 shares in the last quarter. 66.05% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他幾家大型投資者最近也調整了對該公司的持股。Almitas Capital LLC 在第一季度將其在 Lyell Immunopharma 的股份增加了 136.3%。Almitas Capital LLC 目前持有 2,482,606 股該公司的股票，價值 1,336,000 美元，此前在此期間又購買了 1,432,086 股。Nuveen LLC 在第一季度購買了 Lyell Immunopharma 的新股份，價值約 345,000 美元。Acadian Asset Management LLC 在第一季度將其在 Lyell Immunopharma 的持股增加了 204.2%。Acadian Asset Management LLC 目前持有 660,899 股該公司的股票，價值 354,000 美元，此前又購買了 443,614 股。最後，AQR Capital Management LLC 在第一季度將其在 Lyell Immunopharma 的股份增加了 773.5%。AQR Capital Management LLC 目前持有 174,279 股該公司的股票，價值 94,000 美元，此前在上個季度又購買了 154,327 股。目前，66.05% 的股票由機構投資者持有。</p>
</div><p>Get <strong>Lyell Immunopharma</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Lyell Immunopharma</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Several equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Lyell Immunopharma from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Monday, September 1st. HC Wainwright reiterated a &#34;neutral&#34; rating and set a $20.00 target price (up previously from $10.00) on shares of Lyell Immunopharma in a report on Monday. Finally, Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Lyell Immunopharma in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Lyell Immunopharma presently has a consensus rating of &#34;Reduce&#34; and a consensus price target of $20.00.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對該股票發佈了報告。Wall Street Zen 在 9 月 1 日的研究報告中將 Lyell Immunopharma 的股票評級從 “賣出” 上調至 “持有”。HC Wainwright 在週一重申了 “中性” 評級，並將 Lyell Immunopharma 的目標價設定為 20.00 美元（之前為 10.00 美元）。最後，Weiss Ratings 在 10 月 8 日的報告中重申了對 Lyell Immunopharma 的 “賣出（d-）” 評級。一位股票研究分析師對該股票給予了持有評級，另一位則給予了賣出評級。根據 MarketBeat.com 的數據，Lyell Immunopharma 目前的共識評級為 “減持”，共識目標價為 20.00 美元。</p>
</div><p><strong>View Our Latest Report on Lyell Immunopharma</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Lyell Immunopharma 的最新報告</strong></p>
</div><h2>Lyell Immunopharma Price Performance</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 價格表現</h2>
</div><p>Shares of NASDAQ:LYEL opened at $22.72 on Tuesday. The company's 50-day moving average price is $16.54 and its two-hundred day moving average price is $12.41. Lyell Immunopharma, Inc. has a one year low of $7.65 and a one year high of $22.99. The stock has a market capitalization of $482.12 million, a PE ratio of -0.99 and a beta of -0.07.</p>
<div class="lb-trans"><p>NASDAQ:LYEL 的股票在週二開盤價為 22.72 美元。該公司的 50 日移動平均價格為 16.54 美元，200 日移動平均價格為 12.41 美元。Lyell Immunopharma, Inc. 的一年最低價為 7.65 美元，一年最高價為 22.99 美元。該股票的市值為 4.8212 億美元，市盈率為 -0.99，貝塔值為 -0.07。</p>
</div><p>Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($2.13) earnings per share for the quarter, beating the consensus estimate of ($2.81) by $0.68. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%.The company had revenue of $0.02 million during the quarter, compared to analysts' expectations of $0.01 million. On average, analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Lyell Immunopharma (NASDAQ:LYEL - 獲取免費報告) 最近在 11 月 12 日宣佈了其季度財報。該公司報告本季度每股收益為（2.13 美元），超出市場共識預期的（2.81 美元）0.68 美元。Lyell Immunopharma 的股本回報率為 -96.68%，淨利潤率為 -794,292.69%。該公司在本季度的收入為 0.02 萬美元，而分析師的預期為 0.01 萬美元。分析師預計，Lyell Immunopharma, Inc. 在當前財政年度的每股收益將為 -0.78。</p>
</div><h2>Lyell Immunopharma Company Profile</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.</p>
<div class="lb-trans"><p>Lyell Immunopharma, Inc. 是一家臨牀階段的細胞治療公司，開發針對實體腫瘤患者的 T 細胞重編程技術。該公司利用體外基因重編程技術（如 c Jun 過表達和 NR4A3 基因敲除）開發療法，以賦予 T 細胞抵抗疲勞的能力；以及體外表觀遺傳重編程技術，包括 Epi R 以生成具有持久乾性的人羣 T 細胞，以及 Stim R，一種專有合成細胞仿生物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Lyell Immunopharma</li>
<li>How to Calculate Return on Investment (ROI)</li>
<li>D-Wave: Time to Buy the Dip? Or is the Fall Just Starting?</li>
<li>Financial Services Stocks Investing</li>
<li>Hims, Block, and NRG Just Launched Huge Stock Buybacks</li>
<li>What Are the U.K. Market Holidays? How to Invest and Trade</li>
<li>Retail Earnings Roundup: Walmart Scores, Target Slumps in Q3</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Lyell Immunopharma</li>
<li>如何計算投資回報率 (ROI)</li>
<li>D-Wave：是時候買入了嗎？還是下跌才剛剛開始？</li>
<li>金融服務股票投資</li>
<li>Hims、Block 和 NRG 剛剛啓動了大規模股票回購</li>
<li>英國市場假期有哪些？如何投資和交易</li>
<li>零售收益匯總：沃爾瑪表現優異，塔吉特在第三季度下滑</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=LYEL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lyell Immunopharma Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Lyell Immunopharma 嗎？</h2>
</div><p>Before you consider Lyell Immunopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Lyell Immunopharma 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Lyell Immunopharma 並不在名單上。</p>
</div><p>While Lyell Immunopharma currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Lyell Immunopharma 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Foresite Capital Management V LLC 減持了 Lyell Immunopharma, Inc. $LYEL 的股票